Iovance Biotherapeutics Inc Forecast, price target & analysts
Iovance Biotherapeutics Inc Target price 2025 - Analyst rating & recommendation
Iovance Biotherapeutics Inc Classifications & Recommendation:
Iovance Biotherapeutics Inc Price Target
| Target Price | $23.50 |
| Price | $5.26 |
| Potential |
346.77%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Iovance Biotherapeutics Inc 2026 .
The average Iovance Biotherapeutics Inc target price is $23.50.
This is
346.77%
register free of charge
$34.00
546.39%
register free of charge
$7.50
42.59%
register free of charge
|
|
| A rating was issued by 15 analysts: 13 Analysts recommend Iovance Biotherapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Iovance Biotherapeutics Inc stock has an average upside potential 2026 of
346.77%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.19 | 162.47 |
| 13,553.19% | ||
| EBITDA Margin | -35,918.49% | -229.49% |
| 99.36% | ||
| Net Margin | -48,380.82% | -242.76% |
| 99.50% |
14 Analysts have issued a sales forecast Iovance Biotherapeutics Inc 2024 . The average Iovance Biotherapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Iovance Biotherapeutics Inc EBITDA forecast 2024. The average Iovance Biotherapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Iovance Biotherapeutics Inc Analysts have issued a net profit forecast 2024. The average Iovance Biotherapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.89 | -1.29 |
| 24.10% | 31.75% | |
| P/E | negative | |
| EV/Sales | 8.08 |
13 Analysts have issued a Iovance Biotherapeutics Inc forecast for earnings per share. The average Iovance Biotherapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Iovance Biotherapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Iovance Biotherapeutics Inc...
Current Iovance Biotherapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler | Locked ➜ Locked | Locked | Jan 31 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 06 2024 |
| UBS | Locked ➜ Locked | Locked | Oct 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler: Locked ➜ Locked
|
Jan 31 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 06 2024 |
|
Locked
UBS: Locked ➜ Locked
|
Oct 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
